FloSeal Sales To Benefit From Baxter’s Marketing Muscle In $157 Mil. Deal
This article was originally published in The Gray Sheet
Executive Summary
Baxter's $157 mil. stock-for-stock acquisition of Fusion Medical will triple the direct sales force marketing the FloSeal hemostatic sealant